Wall Street expects a year-over-year increase in earnings on higher revenues when Arcutis Biotherapeutics, Inc. (ARQT) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 6, 2025, might help the stock move higher if these key numbers are be ...

Bowman Consulting (BWMN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 6, 2025, might help the stock move higher if these key numbers are better than e ...

Core Viewpoint - The market anticipates a year-over-year decline in Atkore Inc.'s earnings due to lower revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - Atkore is expected to report quarterly earnings of $2.05 per share, reflecting a decline of 49.8% year-over-year, with revenues projected at $699.9 million, down 11.7% from the previous year [3]. - The consensus EPS estimate has been revised down by 7.59% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, making it challenging to predict an earnings beat [10][11]. - The stock currently holds a Zacks Rank of 3, which does not strongly indicate a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Atkore exceeded the expected earnings of $1.50 per share by delivering $1.63, resulting in a surprise of +8.67% [12]. - Over the past four quarters, Atkore has beaten consensus EPS estimates twice [13]. Conclusion - While Atkore does not appear to be a strong candidate for an earnings beat, investors should consider other factors influencing stock performance ahead of the earnings release [16].

The market expects TXO Partners LP (TXO) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if the ...

Xylem (XYL) reported $2.07 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 1.8%. EPS of $1.03 for the same period compares to $0.90 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.04 billion, representing a surprise of +1.26%. The company delivered an EPS surprise of +8.42%, with the consensus EPS estimate being $0.95.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they c ...

NexPoint Residential Trust Inc. (NXRT) came out with quarterly funds from operations (FFO) of $0.84 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to FFO of $0.86 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an FFO surprise of 9.09%. A quarter ago, it was expected that this real estate investment trust would post FFO of $0.80 per share when it actually produced FFO of $0.78, delivering a surprise of -2.50%. Over ...

Core Viewpoint - DexCom, Inc. is set to release its first-quarter 2025 results on May 1, with expectations of revenue growth and potential challenges ahead [1][3][4]. Financial Performance - The Zacks Consensus Estimate for revenues is $1.02 billion, reflecting a 10.3% increase from the previous year [3]. - The consensus estimate for earnings is 33 cents per share, indicating a 3.1% year-over-year growth [3]. - In the last reported quarter, DexCom's earnings missed estimates by 10% but outperformed in three of the last four quarters, with an average surprise of 5.86% [1]. Market Dynamics - DexCom's performance is bolstered by an expanded U.S. prescriber base and improved coverage by major pharmacy benefit managers (PBMs) [5]. - The company has seen a record number of new patient starts and added 50,000 new clinicians in 2024, indicating strong commercial execution [6]. - U.S. revenues improved by 4% year-over-year in the fourth quarter, following a decline in the third quarter [7]. International Expansion - The international segment grew by 17% year-over-year in the last quarter, driven by the launch of G7 in Australia and coverage for Dexcom ONE+ in France and New Zealand [7][8]. - The return to growth in Japan, aided by a new sales structure, is a significant highlight [8]. Product Development - Stelo, an over-the-counter continuous glucose monitor, has gained traction with over 140,000 users in its first four months [8]. - DexCom plans to enhance Stelo's adoption through product iterations and partnerships, including integration with Oura Ring for comprehensive health monitoring [9]. Financial Outlook - DexCom projects full-year 2025 revenue of $4.6 billion, representing organic growth of 14% [10]. - The company anticipates continued margin improvement as it converts its installed base to G7 and scales manufacturing [10]. - DexCom holds a strong cash position of $2.58 billion, providing financial flexibility for strategic initiatives [11].

Altria (MO) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.17 per share. This compares to earnings of $1.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.13%. A quarter ago, it was expected that this owner of Philip Morris USA, the nation's largest cigarette maker would post earnings of $1.27 per share when it actually produced earnings of $1.29, delivering a surprise of 1.5 ...

Entergy (ETR) came out with quarterly earnings of $0.82 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32.26%. A quarter ago, it was expected that this power company would post earnings of $0.63 per share when it actually produced earnings of $0.66, delivering a surprise of 4.76%.Over the last four quarters, the company has ...

For the quarter ended March 2025, Brixmor Property (BRX) reported revenue of $337.51 million, up 5.4% over the same period last year. EPS came in at $0.56, compared to $0.29 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $330.56 million, representing a surprise of +2.11%. The company delivered an EPS surprise of +1.82%, with the consensus EPS estimate being $0.55. View all Key Company Metrics for Brixmor here>>> Shares of Brixmor have returned -1.3% over the past m ...